ClinicalTrials.gg
Status unknownNCT03464682HS-25-C-01Updated Oct 18, 2018

Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia

A Phase 3 interventional study of HS-25 10mg and HS-25 10mg combination with Atorvastatin in Primary Hypercholesterolemia, sponsored by Zhejiang Hisun Pharmaceutical Co. Ltd.. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-18.

Sponsored by Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Feb 2015, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Planned enrollment
15th of 75
720 · median 148
Started
2015
with 2 others
Phase 3
31 of 77
none open now
Registered
68th of 77
by date

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 15th largest by planned enrollment of the 75 interventional ones that give a count, is one of 3 that started in 2015, is one of 31 in phase 3, and was the 68th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

To determine the efficacy of the HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in subjects with LDL-C after a 40-week period of treament.

Read the detailed description

This is a 12-week, randomized, double-blind, double dummy, placebo-controlled study designed to assess the effects of the cholesterol absorption inhibitor HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg) on LDL-C levels in adults who have untreated LDL-C levels ranging from 3.36-4.88mmol/L(130-189 mg/dL)and fasting triglyceride levels \< 350 mg/dL. Eligibility is restricted to 18-70 years old men or women who are using a highly effective birth control method or are not of childbearing potential;subjects with not treated by statins in six months before signature of the informed consent.Subjects with diabetes, a history of myocardial infarction or other clinical evidence of atherosclerotic vascular disease or treated are not eligible for participation in the study.

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are 18 to 70 years of age, male or female using a highly effective method or not of , at Visit 1 (screening visit);
  • LDL-C 3.36mmol/L (130 mg/dL) to 4.88 mmol/L (189 mg/dL) (inclusive) on a cholesterol lowering diet but no lipid modifying drug treatment (statins) for at least 6 weeks before signed written ;
  • A qualifying LDL-C value must be obtained at the beginning and end of the placebo run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the value at Visit 2, higher or lower; the average of both qualifying values must be in the range of 3.36mmol/L (130 mg/dL) to 4.88 mmol/L (189 mg/dL) (inclusive) for inclusion in the study.

Exclusion criteria

Exclusion Criteria:

  • Liver transaminases > 1.5 x .
  • Homozygous Familial Hypercholesterolemia.
  • Subject who was diagnosed as diabetes with aged greater than 40 years old.
  • Subject who was diagnosed as diabetes with one of the following of cardiovascular risk factorss: Hypertention Bp ≥ 140/90mmHg,or smoking, or low HDL-C (1.04mmol/L), or ≥28kg/m2.
  • Women who are pregnant or breast feeding.
  • Atherosclerotic cardiovascular disease including Arteriosclerotic heart disease, Acute coronary syndrome,Coronary artery bypass graft,Coronary angioplastyPeripheral arteriosclerosis,Cerebrovascular accident - history of Severe Endiocrine disease (for example Thyroid function abnormal) - History of a positive test for , or .
  • History of advanced cancer - Arrhythmias need to be treated by medications
  • Had severe injured or surgery in 6 months before study start.
  • Hypersensitive to HS-25 or place.
  • History of intolerance to ezetimibe.
  • Participation other studies in three months.
  • Treatment with a fibric acid derivative (eg, fenofibrate, gemfibrozil), probucol, warfarin, systemic , cyclosporine or other agent within the prior 12 weeks.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
720 participants (estimated)

Study arms

  • Experimental
    HS-25 10mg

    HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks

    Drug: HS-25 10mg · Drug: Placebe of HS-25 and Atorvastatin

  • Experimental
    HS-25 20mg

    HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks

    Drug: HS-25 20mg · Drug: Placebe of HS-25 and Atorvastatin

  • Experimental
    HS-25 10mg combination with Atorvastatin

    HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks

    Drug: HS-25 10mg combination with Atorvastatin · Drug: Atorvastatin 10mg · Drug: Placebe of HS-25 and Atorvastatin

  • Experimental
    HS-25 20mg combination with Atorvastatin

    HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks

    Drug: HS-25 20mg combination with Atorvastatin · Drug: Atorvastatin 10mg

  • Active comparator
    Aorvastatin 10mg

    Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks

    Drug: Atorvastatin 10mg · Drug: Placebe of HS-25 and Atorvastatin

  • Placebo comparator
    Placebo of HS-25 and Aorvastatin

    Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks

    Drug: Placebe of HS-25 and Atorvastatin

Interventions

  • HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet

  • DrugHS-25 10mg combination with Atorvastatin

    Drug pages: HS-25 · Atorvastatin

    HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet

  • DrugHS-25 20mg combination with Atorvastatin

    Drug pages: HS-25 · Atorvastatin

    HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet

  • Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets

  • HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet

  • DrugPlacebe of HS-25 and Atorvastatin

    Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets

06

What researchers measure

Primary outcomes

  1. Percent change of LDL-C

    Percent change in LDL-C from baseline to week 12 for each group

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change of LDL-C

    Percent change in LDL-C from baseline to week 2, 4, 8, 18, 24, 38, 52 for each group

    Time frame: 52 weeks ( including 2, 4, 8, 18, 24, 38, 52 weeks)

  2. Percent change of Non-HDL-C

    Percent change in Non-HDL-C from baseline to week 2, 4, 8, 12, 18, 24, 38, 52 for each group

    Time frame: 52 weeks ( including 2, 4, 8, 12, 18, 24, 38, 52 weeks)

  3. Percent change of HDL-C

    Percent change in HDL-C from baseline to week 2, 4, 8, 12, 18, 24, 38, 52 for each group

    Time frame: 52 weeks ( including 2, 4, 8, 12, 18, 24, 38, 52 weeks)

  4. Percent change of TC, TG, Apo B, Apo Al

    Percent change in TC, TG, Apo B, Apo Al from baseline to week 2, 4, 8, 12, 18, 24, 38, 52 for each group

    Time frame: 52 weeks ( including 2, 4, 8, 12, 18, 24, 38, 52 weeks)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2015 (actual). Primary completion is estimated for Dec 2018, 46 months after the start.

Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 46 months is above that.

Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2018
First posted
Mar 14, 2018
StartActual
Feb 28, 2015
Primary completionEst.
Dec 28, 2018
CompletionEst.
May 28, 2019
Last update
Oct 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03464682
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Feb 28, 2015
Primary completion
Dec 28, 2018 (estimated)
Completion
May 28, 2019 (estimated)
Last update
Oct 18, 2018

Study contacts

Jianan Wang
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HS-25 · Atorvastatin

Start the discussion